2024
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, Tsai N, Synold T, Feng Y, Kalu C, Sedrak M, Yee L. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Research And Treatment 2024, 205: 61-73. PMID: 38280052, PMCID: PMC11062803, DOI: 10.1007/s10549-023-07223-4.Peer-Reviewed Original ResearchAI-induced arthralgiaBrief Pain Inventory-Short FormRandomized placebo-controlledPostmenopausal womenPlacebo-controlledBreast cancerDouble-blind pilot trialDouble-blind clinical trialGrip strengthReduced risk of recurrenceDiscontinuation of treatmentRisk of recurrenceGastrointestinal adverse effectsPilot trialPlasma curcuminInflammation-related conditionsPatient-reported outcome measuresSerum estradiolWell-toleratedEstrone levelsPurposeAromatase inhibitorsTreatment armsRandomized trialsT0-T3Study agents
2020
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors
Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas 2020, 144: 37-44. PMID: 33358206, PMCID: PMC7773136, DOI: 10.1016/j.maturitas.2020.10.018.Peer-Reviewed Original ResearchConceptsGynecologic cancer survivorsFemale Sexual Functioning IndexVaginal Assessment ScaleCancer survivorsLaser therapyTreatment armsSexual functionFractional COMedian total FSFI scoreMedian UDI-6 scoreRandomized sham-controlled trialUDI-6 scoresUrinary Distress InventorySerious adverse eventsSham-controlled trialProportion of patientsMedian VAS scoreTotal FSFI scoreFractional CO2 laser therapyCO2 laser therapyLaser treatmentPreliminary evidenceAdenocarcinoma histologyUrinary symptomsAdverse events
2017
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain
Lustberg M, Orchard T, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro C, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Research And Treatment 2017, 167: 709-718. PMID: 29101597, PMCID: PMC5809189, DOI: 10.1007/s10549-017-4559-z.Peer-Reviewed Original ResearchConceptsQuality of lifeJoint symptomsRandomized placebo-controlled pilot trialBrief Pain Inventory-Short FormPostmenopausal breast cancer patientsRed blood cell (RBC) nPlacebo-controlled pilot trialFACT-ES scoresPlacebo-controlled studyPain severity scoreBreast cancer survivorsBreast cancer patientsAnti-inflammatory propertiesAdjuvant AICommon toxicitiesFACT-ESPurposeAromatase inhibitorsPrimary endpointDrug adherencePill countSecondary outcomesMusculoskeletal painTreatment armsCancer survivorsFatty acids